soriatane การใช้

• Soriatane is already available in 24 countries around the world.
• Taken the drug Soriatane ( for three years ).
• Roche officials said they plan to take etretinate off the market when Soriatane becomes available.
• Soriatane is designed to improve on a Roche psoriasis drug currently on the market known as Tegison or etretinate.
• The company and FDA, though, disagreed over how long women should wait to become pregnant after they stop taking Soriatane.
• Soriatane, or acitretin, is designed to improve on a Roche psoriasis drug currently on the market known as Tegison or etretinate.
• Gaithersburg, Maryland : The Food and Drug Administration's Dermatologic and Ophthalmic Drugs Advisory Committee discusses labeling issues concerning Roche Holding AG's Soriatane.
• Women using Roche Pharmaceuticals'Soriatane, the newest such drug and one safer than its predecessors, are still cautioned not to become pregnant for three years after treatment stops.
• Soriatane won FDA approval in October, after several years of review at the agency, for patients with psoriasis, a condition marked by sores and red, scaly patches on the skin.
• The Food and Drug Administration approved the drug, known as Soriatane or acitretin, in October for patients with psoriasis, a condition marked by sores and red, scaly patches on the skin.
• Women taking Roche Holding AG's new psoriasis drug Soriatane should avoid becoming pregnant for at least three years after they stop using the drug, members of a Food and Drug Administration advisory panel said today.
• Though Soriatane generally doesn't stay in the body as long as etretinate, some women appear to effectively process Soriatane in a way that produces etretinate in the bloodstream, therefore posing potentially greater risks to unborn children even years after stopping Soriatane, the FDA said.
• Though Soriatane generally doesn't stay in the body as long as etretinate, some women appear to effectively process Soriatane in a way that produces etretinate in the bloodstream, therefore posing potentially greater risks to unborn children even years after stopping Soriatane, the FDA said.
• Though Soriatane generally doesn't stay in the body as long as etretinate, some women appear to effectively process Soriatane in a way that produces etretinate in the bloodstream, therefore posing potentially greater risks to unborn children even years after stopping Soriatane, the FDA said.
• Though Soriatane generally doesn't stay in the body as long as etretinate, some women appear to effectively process Soriatane in a way that produces etretinate in the bloodstream, therefore posing potentially greater risks to unborn children even years after stopping Soriatane, the FDA said in April.
• Though Soriatane generally doesn't stay in the body as long as etretinate, some women appear to effectively process Soriatane in a way that produces etretinate in the bloodstream, therefore posing potentially greater risks to unborn children even years after stopping Soriatane, the FDA said in April.
• Though Soriatane generally doesn't stay in the body as long as etretinate, some women appear to effectively process Soriatane in a way that produces etretinate in the bloodstream, therefore posing potentially greater risks to unborn children even years after stopping Soriatane, the FDA said in April.